Key result
Pharmacotherapy for heart failure in older adults is reviewed, noting that while >50% of hospitalizations occur in patients over 75 years, most major clinical trials target middle-aged patients.
This review outlines recommended pharmacological approaches for managing systolic and diastolic heart failure specifically in elderly patients.
Answers are grounded in this paper and cite their sources.
Evidence for HF pharmacotherapy in patients >75 remains limited; leaves open optimal strategies pending age-specific trials.
Heart failure is a disorder that predominantly affects older adults, with more than 50% of heart failure hospitalizations occurring in persons over 75 years of age. Unfortunately, most of the major heart failure clinical trials have targeted middle-aged patients with systolic heart failure, and the applicability of these studies to elderly patients, particularly those with preserved left ventricular systolic function, remains uncertain. In this paper, current data on the pharmacotherapy of heart failure in older adults are reviewed, recommended approaches to managing systolic and diastolic heart failure are outlined, and the importance of preventive measures is emphasized.
No takes yet. Share an insight, caveat, or question.
Michael W. Rich (2003) conducted a review in Heart failure. Pharmacotherapy was evaluated. Pharmacotherapy for heart failure in older adults is reviewed, noting that while >50% of hospitalizations occur in patients over 75 years, most major clinical trials target middle-aged patients.
Synapse has enriched 10 related papers. Consider them for comparative context: